Exploring Patient Viewpoints to Optimize Implementation of a Biological Therapy for Atrial Fibrillation Prevention.

Area of Science:

• Biomedical research
• Regenerative medicine
• Patient-centered outcomes

Background:

• Patient acceptance is key for novel therapeutic translation.
• Extracellular vesicles (EVs) show promise as a biological therapy for postoperative atrial fibrillation (AF).
• Understanding patient attitudes towards EV therapy is essential.

Purpose of the Study:

• To evaluate patient acceptability of EV therapy for preventing postoperative AF.
• To identify patient attitudes and information needs regarding EV therapy.
• To explore factors influencing patient acceptance of this novel intervention.

Main Methods:

• Patients engaged with prerecorded presentations, virtual focus groups, and surveys.
• Assessments were conducted pre- and post-educational interventions.
• Data collected on understanding, attitudes, and willingness to participate in trials.

Main Results:

• Initial unfamiliarity with postoperative AF and biological therapies was common.
• Educational interventions significantly improved participant understanding and comprehension.
• A majority of participants showed increased acceptance of EV therapy and willingness to join clinical trials.
• Key concerns included risks, side effects, source, dosing, and HIV/allergy risks.

Conclusions:

• Patient education and addressing concerns are vital for accepting EV therapy for postoperative AF.
• Involving the patient's circle of care enhances therapeutic acceptance.
• Patient-centered approaches accelerate the clinical translation of novel therapies like EVs.